SIAPS conducted a review of regulatory and quality assurance efforts in the GMS with the following objectives—
- To inform PMI of past and current initiatives to improve the capacity of the region to combat counterfeit, substandard, and banned antimalarial medicines
- To understand the current barriers to effective medicine quality control for malaria
- To recommend specific areas of focus or interventions to further improve regional and country capacity to combat counterfeit, substandard, and banned or illegal antimalarial medicines
